US Broker Ratings

Medtronic plc (MDT) Stock Analysis: A 41.83% Potential Upside with Strong Buy Ratings

Medtronic plc (NYSE: MDT), a global leader in the medical devices industry, is attracting significant investor interest with an impressive potential upside of 41.83%. Headquartered in Galway, Ireland, Medtronic’s market..

Insulet Corporation (PODD) Stock Analysis: A 62% Potential Upside Beckons Investors

Insulet Corporation (NASDAQ: PODD) stands out in the healthcare sector, particularly in the medical devices industry, with its innovative insulin delivery systems. The company’s flagship products, such as the Omnipod..

Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Giant with 27.84% Potential Upside

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) stands as a formidable player in the biotechnology sector, renowned for its focus on transformative medicines targeting serious diseases. With a market capitalization of $109.09..

IDEXX Laboratories (IDXX) Stock Analysis: Unveiling a 26.61% Potential Upside for Investors

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a prominent player in the healthcare sector, specifically within the diagnostics and research industry, presents a compelling case for investors with its robust market presence..

Novartis AG (NVS) Stock Analysis: Evaluating a Potential 5.37% Upside in a Healthcare Giant

Novartis AG (NVS), a titan in the global healthcare sector, stands as a formidable presence in the pharmaceutical industry with a market capitalization of $278.64 billion. Headquartered in Basel, Switzerland,..

Eli Lilly and Company (LLY) Stock Analysis: A Strong Buy with 27% Upside Potential

Investors are keeping a close eye on Eli Lilly and Company (NYSE: LLY), a titan in the healthcare sector with a market capitalization of $845.77 billion. Known for its robust..

Thermo Fisher Scientific Inc (TMO): An Investor Outlook with Strong Buy Ratings and Robust Revenue Growth

Thermo Fisher Scientific Inc (NYSE: TMO), a dominant player in the healthcare sector, continues to captivate investors with its robust performance in the diagnostics and research industry. Headquartered in Waltham,..

Abivax SA (ABVX) Stock Analysis: Unpacking the 24.51% Potential Upside Amidst Strong Buy Ratings

Abivax SA (ABVX), a trailblazer in the biotechnology sector, has captured investor attention with its promising potential upside of 24.51%. Headquartered in Paris, France, this clinical-stage biotechnology company is making..

Maze Therapeutics, Inc. (MAZE) Stock Analysis: Exploring a Potential 149.49% Upside in Biotech

Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company headquartered in South San Francisco, has garnered significant attention in the biotechnology sector for its innovative approach to treating kidney and metabolic..

Fortrea Holdings Inc. (FTRE) Stock Analysis: Exploring Growth Potential Amidst a $1.47 Billion Market Cap

Fortrea Holdings Inc. (NASDAQ: FTRE), a relatively new player in the biotechnology sector, is garnering attention from investors with its promising growth potential and strategic focus. Headquartered in Durham, North..

Myriad Genetics, Inc. (MYGN) Stock Analysis: Evaluating a Promising 77.94% Upside Potential

Myriad Genetics, Inc. (NASDAQ: MYGN) is a notable player in the healthcare sector, specifically in the diagnostics and research industry. Headquartered in Salt Lake City, Utah, the company specializes in..

Prothena Corporation plc (PRTA) Stock Analysis: Biotechnology Innovator with a 99.62% Potential Upside

Prothena Corporation plc (NASDAQ: PRTA) has emerged as a significant player within the biotechnology sector, captivating investor attention with its promising pipeline and a substantial potential upside of 99.62%. This..

Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: Investors Eye 107% Upside Potential

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) presents a compelling opportunity for investors interested in the biotechnology sector, particularly those focused on companies addressing rare diseases. With a market capitalization of $650.27..

Standard BioTools Inc. (LAB) Stock Analysis: A 55% Potential Upside Beckons Investors

Standard BioTools Inc. (NASDAQ: LAB), a player in the medical devices sector, offers a compelling opportunity for investors with an eye for high-potential biotech stocks. Headquartered in Boston, Massachusetts, the..

Arbutus Biopharma Corporation (ABUS) Stock Analysis: Exploring a 20% Potential Upside in the Biotech Sector

Arbutus Biopharma Corporation (NASDAQ: ABUS) is gaining attention in the biotechnology sector, driven by its promising pipeline focused on novel therapeutics for infectious diseases, particularly chronic Hepatitis B. With a..

OrthoPediatrics Corp. (KIDS) Stock Analysis: Navigating a 40% Potential Upside with Strategic Growth

OrthoPediatrics Corp. (NASDAQ: KIDS), a prominent player in the healthcare sector focusing on medical devices, presents a compelling opportunity for investors seeking growth in the pediatric orthopedic market. With a..

Kamada Ltd. (KMDA) Stock Analysis: Unveiling a 57% Potential Upside in the Healthcare Sector

For investors seeking opportunities in the healthcare sector, Kamada Ltd. (NASDAQ: KMDA) presents a compelling case with its significant potential upside of 57.38%. This Israeli-based company, operating in the drug..

SIGA Technologies Inc. (SIGA) Stock Analysis: Assessing Opportunities in the Health Security Sector

SIGA Technologies Inc. (NASDAQ: SIGA), a prominent player in the health security sector, has attracted attention with its commercial-stage pharmaceutical operations, particularly centered around its antiviral drug, TPOXX. As a..

MeiraGTx Holdings plc (MGTX) Stock Analysis: Unpacking a Promising 188% Upside in Biotech Innovation

Investors with a keen eye on the biotechnology sector should take a closer look at MeiraGTx Holdings plc (NASDAQ: MGTX). Known for its cutting-edge work in genetic medicines, MeiraGTx stands..

Cel-Sci Corporation (CVM) Stock Analysis: Exploring the Potential of a Biotech Challenger with a Unique Immunotherapy Approach

Cel-Sci Corporation (NASDAQ: CVM), a clinical-stage biotechnology firm, is carving a niche in the healthcare sector with its innovative approach to cancer treatment. Headquartered in Vienna, Virginia, this company is..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds